Table 1 Baseline characteristics of participants according to Lp-PLA2 quartiles.
Total | Lp-PLA2 quartiles | |||||
|---|---|---|---|---|---|---|
Q1 | Q2 | Q3 | Q4 | P value | ||
Number of subjects | 343 | 344 | 344 | 343 | ||
MMSE <24, n (%) | 107 (7.8) | 9 (2.6) | 18 (5.2) | 27 (7.8) | 53 (15.5) | <0.0001 |
Lp-PLA2 mass, ng/ml | 165.91 ± 113.16 | 127.66 ± 2.67 | 135.58 ± 2.45 | 147.06 ± 4.71 | 253.50 ± 202.31 | <0.0001 |
Age, years | 59.09 ± 10.88 | 55.26 ± 8.47 | 57.47 ± 9.74 | 59.87 ± 10.61 | 63.75 ± 12.48 | <0.0001 |
Male, n (%) | 987 (71.8) | 254 (74.1) | 257 (74.7) | 237 (68.9) | 239 (69.7) | 0.2127 |
Education, n (%) | ||||||
Illiteracy or primary school | 223 (16.2) | 50 (14.6) | 48 (14.0) | 53 (15.4) | 72 (21.0) | 0.1485 |
Middle school | 599 (43.6) | 160 (46.7) | 153 (44.5) | 144 (41.9) | 142 (41.4) | |
High school or higher | 552 (40.2) | 133 (38.8) | 143 (41.6) | 147 (42.7) | 129 (37.6) | |
Working environment with dust, n (%) | 339 (24.7) | 106 (30.9) | 74 (21.5) | 86 (25.0) | 73 (21.28) | 0.0109 |
Current smoking, n (%) | 534 (38.9) | 158 (46.1) | 146 (42.4) | 113 (32.9) | 117 (34.1) | 0.0005 |
Current alcohol use, n (%) | 537 (39.1) | 150 (43.7) | 143 (41.6) | 123 (35.8) | 121 (35.3) | 0.0528 |
Hyperlipidemia, n (%) | 679 (49.4) | 186 (54.2) | 177 (51.5) | 168 (48.8) | 148 (43.2) | 0.027 |
Lipid-lowering drugs use, n (%) | 23 (1.7) | 8 (2.3) | 5 (1.5) | 3 (0.9) | 7 (2.0) | 0.4524 |
Hypertension, n (%) | 785 (57.1) | 178 (51.9) | 179 (52.0) | 219 (63.7) | 209 (60.9) | 0.0014 |
Anti-hypertensive drugs use, n (%) | 356 (25.9) | 68 (19.8) | 74 (21.5) | 114 (33.1) | 100 (29.2) | <0.0001 |
Diabetes, n (%) | 216 (15.7) | 47 (13.7) | 55 (16.0) | 64 (18.6) | 50 (14.6) | 0.3117 |
Anti-diabetic drugs use, n (%) | 124 (9.0) | 23 (6.7) | 25 (7.3) | 47 (13.7) | 29 (8.5) | 0.0054 |
Physical inactivity, n (%) | 493 (35.9) | 129 (37.6) | 114 (33.1) | 114 (33.1) | 136 (39.6) | 0.1862 |
BMI, kg/m2 | 24.97 ± 3.15 | 25.41 ± 2.89 | 25.13 ± 3.19 | 24.98 ± 3.08 | 24.35 ± 3.33 | <0.0001 |
LDL, mmol/L | 2.68 ± 0.82 | 2.76 ± 0.84 | 2.70 ± 0.73 | 2.64 ± 0.71 | 2.61 ± 0.96 | 0.0432 |
HDL, mmol/L | 1.62 ± 0.45 | 1.60 ± 0.44 | 1.56 ± 0.44 | 1.61 ± 0.41 | 1.69 ± 0.48 | 0.0057 |
TG, mmol/L | 1.69 ± 1.42 | 1.87 ± 1.59 | 1.79 ± 1.41 | 1.62 ± 1.41 | 1.47 ± 1.23 | <0.0001 |
TC, mmol/L | 5.20 ± 1.06 | 5.29 ± 1.25 | 5.23 ± 0.99 | 5.15 ± 0.96 | 5.16 ± 1.02 | 0.7490 |
FBG, mmol/L | 5.70 ± 1.61 | 5.68 ± 1.50 | 5.75 ± 1.65 | 5.81 ± 1.83 | 5.54 ± 1.45 | 0.0751 |
White cell count, × 109/L | 6.38 ± 1.63 | 6.49 ± 1.58 | 6.45 ± 1.72 | 6.40 ± 1.58 | 6.16 ± 1.63 | 0.0293 |
ALT, U/L | 18.58 ± 14.71 | 19.10 ± 12.17 | 18.70 ± 11.75 | 20.26 ± 21.72 | 16.26 ± 10.04 | <0.0001 |
CRP, mg/L | 2.17 ± 3.19 | 1.94 ± 2.66 | 1.98 ± 2.50 | 2.19 ± 3.11 | 2.57 ± 4.18 | 0.5317 |
Homocysteine, umol/l | 17.04 ± 9.44 | 16.81 ± 10.30 | 16.71 ± 9.61 | 15.39 ± 7.90 | 19.25 ± 9.43 | <0.0001 |
